Discrepancy between results of randomized control studies and retrospective analysis The case of statin therapy effect on one-year mortality in patients with decompensated heart failure

被引:6
作者
Nevzorov, Roman [1 ]
Novack, Victor [1 ,2 ]
Henkin, Yaakov [3 ]
Kobal, Sergio L. [3 ]
Jotkowitz, Alan [1 ]
Porath, Avi [1 ]
机构
[1] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Univ Med Ctr, Dept Internal Med F, Beer Sheva, Israel
[2] Harvard Clin Res Inst, Boston, MA USA
[3] Ben Gurion Univ Negev, Fac Hlth Sci, Soroka Univ Med Ctr, Dept Cardiol, Beer Sheva, Israel
关键词
Heart failure; Statins; Ischemic heart disease; ACUTE MYOCARDIAL-INFARCTION; A REDUCTASE INHIBITOR; CONTROLLED-TRIAL; HOMOCYSTEINE; SURVIVAL; CARDIOMYOPATHY; ROSUVASTATIN; PRAVASTATIN;
D O I
10.1016/j.ejim.2009.03.001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In view of the recent reports on a lack of protective effect of statin therapy on clinical outcomes in patients with heart failure, the present study investigated the impact of statin therapy before admission on one-year survival of patients hospitalized due to decompensated heart failure in two groups of patients: with and without ischemic heart disease. Methods: We performed a retrospective cohort analysis of 887 consecutive patients older than 18 years hospitalized with decompensated heart failure between 11/December 2001 and 06/June 2005. Two groups of patients were compared: those who received statins within 3 months before the admission (S) and those who did not (NS). The primary outcome was one-year all-cause mortality. To adjust for a potential misbalance between S and NS groups in baseline characteristics, a propensity score for statin therapy was incorporated into the survival model. Results: Two hundred eighty-one patients (31.7%) received statins prior to admission. Patients with ischemic heart disease (IHD) (656/887 subjects, 74%) had higher rate of S therapy as compared to the rest 36.3% vs. 18.6%, p<0.001. Overall one-year mortality rate in the S group was 21% vs. 31.8% in the NS group, p<0.001. In the subgroup of patients with IHD, statins were protective after adjustment for comorbidities and propensity score (hazard ratio [HR], 0.66; 95% CI 0.4-0.97), but in patients with non-ischemic HF statin therapy was not associated with a protective effect (HR 0.77; 95% CI 0.38-1.6). Conclusions: In our study statins' protective effect on one-year survival in HF patients is restricted to patients with IHD. This stands in disagreement with the results of the randomized trials showing no effect of statin therapy. Statin use may be a marker of better health care and despite an extensive adjustment for baseline characteristics, unaccounted bias inherent to retrospective studies may explain the discrepancy in the results. (C) 2009 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:494 / 498
页数:5
相关论文
共 24 条
[1]   Effects of conjugated, equine estrogen in postmenopausal women with hysterectomy - The women's health initiative randomized controlled trial [J].
Anderson, GL ;
Limacher, M ;
Assaf, AR ;
Bassford, T ;
Beresford, SAA ;
Black, H ;
Bonds, D ;
Brunner, R ;
Brzyski, R ;
Caan, B ;
Chlebowski, R ;
Curb, D ;
Gass, M ;
Hays, J ;
Heiss, G ;
Hendrix, S ;
Howard, BV ;
Hsia, J ;
Hubbell, A ;
Jackson, R ;
Johnson, KC ;
Judd, H ;
Kotchen, JM ;
Kuller, L ;
LaCroix, AZ ;
Lane, D ;
Langer, RD ;
Lasser, N ;
Lewis, CE ;
Manson, J ;
Margolis, K ;
Ockene, J ;
O'Sullivan, MJ ;
Phillips, L ;
Prentice, RL ;
Ritenbaugh, C ;
Robbins, J ;
Rossouw, JE ;
Sarto, G ;
Stefanick, ML ;
Van Horn, L ;
Wactawski-Wende, J ;
Wallace, R ;
Wassertheil-Smoller, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 291 (14) :1701-1712
[2]   Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction [J].
Bauersachs, J ;
Galuppo, P ;
Fraccarollo, D ;
Christ, M ;
Ertl, G .
CIRCULATION, 2001, 104 (09) :982-985
[3]   Homocysteine lowering and cardiovascular events after acute myocardial infarction [J].
Bonaa, KH ;
Njolstad, I ;
Ueland, PM ;
Schirmer, H ;
Tverdal, A ;
Steigen, T ;
Wang, H ;
Nordrehaug, JE ;
Arnesen, E ;
Rasmussen, K .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (15) :1578-1588
[4]   Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor [J].
Dechend, R ;
Fiebeler, A ;
Park, JK ;
Muller, DN ;
Theuer, J ;
Mervaala, E ;
Bieringer, M ;
Gulba, D ;
Dietz, R ;
Luft, FC ;
Haller, H .
CIRCULATION, 2001, 104 (05) :576-581
[5]   Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the beta blocker evaluation of survival trial [BEST]) [J].
Domanski, Michael ;
Coady, Sean ;
Fleg, Jerome ;
Tian, Xin ;
Sachdev, Vandana .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (10) :1448-1450
[6]   Statins and mortality among elderly patients hospitalized with heart failure [J].
Foody, JM ;
Shah, R ;
Galusha, D ;
Masoudi, FA ;
Havranek, EP ;
Krumholz, HM .
CIRCULATION, 2006, 113 (08) :1086-1092
[7]   Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction [J].
Hayashidani, S ;
Tsutsui, H ;
Shiomi, T ;
Suematsu, N ;
Kinugawa, S ;
Ide, T ;
Wen, J ;
Takeshita, A .
CIRCULATION, 2002, 105 (07) :868-873
[8]   Effect of combined statin and beta-blocker treatment on one-year morbidity and mortality after acute myocardial infarction associated with heart failure [J].
Hognestad, A ;
Dickstein, K ;
Myhre, E ;
Snapinn, S ;
Kjekshus, J .
AMERICAN JOURNAL OF CARDIOLOGY, 2004, 93 (05) :603-606
[9]   Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure [J].
Horwich, TB ;
MacLellan, WR ;
Fonarow, GC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (04) :642-648
[10]  
Kjekshus J, 1997, J Card Fail, V3, P249, DOI 10.1016/S1071-9164(97)90022-1